Inmed Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
InMed Pharmaceuticals Inc. announces its 2025 Annual General and Special Meeting to be held virtually on December 17, 2025, seeking shareholder approval for director elections, auditor appointment, and a significant share issuance under a standby equity purchase agreement.
NASDAQ
InMed Pharmaceuticals Inc. announces its Annual General and Special Meeting on December 17, 2025, seeking shareholder approval for director elections, auditor reappointment, and a potential equity issuance of 20% or more of common shares.
NASDAQ
InMed Pharmaceuticals Inc. is reminding shareholders to vote on a proposal to approve the potential issuance of 20% or more of its common shares under a Standby Equity Purchase Agreement (SEPA) to secure future funding.
NASDAQ
InMed Pharmaceuticals is seeking shareholder approval to potentially issue 20% or more of its common shares under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (Yorkville), as required by Nasdaq Listing Rules.
NASDAQ
InMed Pharmaceuticals will hold its annual general meeting virtually on December 18, 2024, to discuss financial statements, elect directors, and appoint auditors.
NASDAQ
InMed Pharmaceuticals will hold its 2024 Annual General Meeting virtually on December 18, 2024, and is using notice-and-access rules for delivering meeting materials to shareholders.